| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/17/2003 | US20030135055 Inhibitors of factors Xa and VIIa |
| 07/17/2003 | US20030135053 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics |
| 07/17/2003 | US20030135049 Preparing camptothecin intermediates |
| 07/17/2003 | US20030135045 Glycoprotein IIb/IIIa antagonists |
| 07/17/2003 | US20030135044 Novel gamma secretase inhibitors |
| 07/17/2003 | US20030135043 Novel synthesis and crystallization of piperazine ring-containing compounds |
| 07/17/2003 | US20030135042 Atypical antipsychotic agents having low affinity for the D2 Receptor |
| 07/17/2003 | US20030134918 Absorbent articles comprising supercritical fluid treated HIPE, I-HIPE foams and other foams |
| 07/17/2003 | US20030134908 Pharmaceutical compositions |
| 07/17/2003 | US20030134907 Preventing or treating ischemic disease or ischemia/reperfusion injury; has geranylgeranylacetone as an active ingredient |
| 07/17/2003 | US20030134906 Modified release pharmaceutical composition containing bupropion HCI as active substance |
| 07/17/2003 | US20030134905 Preferably, the virus is HSV1 or HSV2. |
| 07/17/2003 | US20030134904 Inhibitors of RNase P proteins as antibacterial compounds |
| 07/17/2003 | US20030134903 Substituted aminoalkanoate or substituted aminoalkyl alkanoate as a penetration enhancer a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. |
| 07/17/2003 | US20030134901 Lipoxin compounds and their use in treating cell proliferative disorders |
| 07/17/2003 | US20030134899 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect |
| 07/17/2003 | US20030134898 N-Acetylsulfamic acid derivatives |
| 07/17/2003 | US20030134895 Method for the preparation of citalopram |
| 07/17/2003 | US20030134894 Administering a haloenol lactone as an anandamide amidohydrolase inhibitor; prefered is E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl) -2H-pyrane-2-one |
| 07/17/2003 | US20030134893 Combination chemotherapy |
| 07/17/2003 | US20030134892 Compositions for treatment of head and neck cancers, and methods of making and using the same |
| 07/17/2003 | US20030134891 N,N'-bis(2-carboxytetramethylene)adipamide or cyclic alkylene esters for use in the treatment or prevention of central and systemic amyloidosis. |
| 07/17/2003 | US20030134889 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 07/17/2003 | US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc. |
| 07/17/2003 | US20030134887 Orally administering celecoxib formulated in such a way as to provide a blood plasma concentration profile of celecoxib of 250 ng/ml in not later than 30 minutes |
| 07/17/2003 | US20030134886 Pharmaceutically active compounds |
| 07/17/2003 | US20030134884 Benzyloxyiminohydrocarbylcarboxy compounds, such as E-4-(4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino)--4-phenylbutyric acid |
| 07/17/2003 | US20030134882 Use of C2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity |
| 07/17/2003 | US20030134881 Substituted with a thio, sulfoxy or sulfonyl group |
| 07/17/2003 | US20030134880 Novel cd23 inhibitors |
| 07/17/2003 | US20030134879 Substituted with a thio, sulfoxy or sulfonyl group |
| 07/17/2003 | US20030134878 Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith |
| 07/17/2003 | US20030134876 Inhibiting TNF alpha |
| 07/17/2003 | US20030134875 Production of agglomerates |
| 07/17/2003 | US20030134874 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/17/2003 | US20030134873 8-phenyl-(1,2,4)triazolo(1,5-a)pyridin-2-yl)-benzamide derivatives |
| 07/17/2003 | US20030134872 2-acetoxy-5-(alpha-cyclopropylcarbonyl-O-fluorobenzyl)--4,5,6,7 -tetrahydrothieno(3,2-c)-pyridine, particularly the hydrochloride and the maleate |
| 07/17/2003 | US20030134869 Novel therapeutic use of nicergoline |
| 07/17/2003 | US20030134868 Prevention of addiction in pain management |
| 07/17/2003 | US20030134866 A 2-(piperidinyl)methyl-2,3-dihydroimidazo(1,2-c)-quinazolin-5(6H)-one or salt |
| 07/17/2003 | US20030134865 Modulation of histone deacetylase |
| 07/17/2003 | US20030134863 Preventives/remedies for alzheimer's disease |
| 07/17/2003 | US20030134862 Compounds |
| 07/17/2003 | US20030134861 Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 07/17/2003 | US20030134860 Piperazine-containing macrocyclic compounds |
| 07/17/2003 | US20030134859 Substituted 2-chloro-5-nitrobenzamides; treating retrograde osteoporosis and diabetes mellitus |
| 07/17/2003 | US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease |
| 07/17/2003 | US20030134855 P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and ADHD |
| 07/17/2003 | US20030134854 Treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, neuroprotection, Parkinson's disease, and attention deficit hyperactivity disorder. |
| 07/17/2003 | US20030134852 Halogen substituted tetracyclic tetrahydrofuran derivatives |
| 07/17/2003 | US20030134851 Methods and compositions for providing glutamine |
| 07/17/2003 | US20030134850 Hydrazinyl and nitrogen oxide pyrazoles |
| 07/17/2003 | US20030134849 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 07/17/2003 | US20030134848 Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators |
| 07/17/2003 | US20030134847 New polycyclic azaindole compounds |
| 07/17/2003 | US20030134846 Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
| 07/17/2003 | US20030134844 Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome |
| 07/17/2003 | US20030134842 Method of treating or preventing an inflammatory disease, said method comprising the step of administering to a subject suffering from an inflammatory disease a therapeutically effective amount of a compound having the formula: |
| 07/17/2003 | US20030134841 Succinoylamino lactams as inhibitors of A-beta protein production |
| 07/17/2003 | US20030134840 Novel compounds |
| 07/17/2003 | US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 07/17/2003 | US20030134838 Treatment of illnesses in which beta -amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof. |
| 07/17/2003 | US20030134837 Pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them and anticancer agents |
| 07/17/2003 | US20030134836 Substituted arylamine derivatives and methods of use |
| 07/17/2003 | US20030134835 Method of treating a diabetic condition by administering a therapeutically effective amount of a histamine-3 receptor antagonist, including benzofuran and benzopyran derivatives of formula (I), aminoalkoxybiphenylcarboxamide compounds of |
| 07/17/2003 | US20030134834 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain |
| 07/17/2003 | US20030134833 Substance for lowering high cholesterol level in serum and methods for preparing and using the same |
| 07/17/2003 | US20030134832 Synthetic steroids and particularly to oestrene derivatives. Specifically, the invention relates to stabilized compositions of tibolone (7 alpha , 17 alpha 17-hydroxy-7-methyl-19-nor-17-pregn 5(10)-en-20-yn-3-one and |
| 07/17/2003 | US20030134830 Bioavailable prodrugs of androgenic steroids and related method |
| 07/17/2003 | US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate, |
| 07/17/2003 | US20030134828 Composition and method for increasing in vivo androgen concentration |
| 07/17/2003 | US20030134825 Food product supplemented with proteoglycan precursors |
| 07/17/2003 | US20030134823 Heparin with average molecular mass |
| 07/17/2003 | US20030134821 Promoters of neural regeneration |
| 07/17/2003 | US20030134820 Promoting neural cell growth and/or regeneration. The general methods involve contacting with an activator of a cyclic nucleotide dependent protein kinase a neural cell subject to growth repulsion mediated by a neural cell growth repulsion |
| 07/17/2003 | US20030134812 Bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using alpha 1d-adrenergic receptor ( alpha 1dAR) antagonists. The invention further relates to a method of screening compounds |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134805 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 07/17/2003 | US20030134804 Rehydrating formulation |
| 07/17/2003 | US20030134803 Contraceptive devices that use sulfonated compounds that interact with sperm to inhibit fertilization. Natural contraceptive methods, compositions and contraceptive devices are also included. These natural contraceptives use |
| 07/17/2003 | US20030134802 Novel effectors of dipepetidyl peptidase IV |
| 07/17/2003 | US20030134801 Pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants. |
| 07/17/2003 | US20030134793 Water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly- aspartic acid or -lysine. Methods of using the compositions for treatment of |
| 07/17/2003 | US20030134785 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 07/17/2003 | US20030134781 Topical application of compositions to skin in need thereof, where the compositions comprise at least one peptide copper complex, or at least one peptide copper complex in combination with retinol, at least one retinol derivative, or a mixture. |
| 07/17/2003 | US20030134780 Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof |
| 07/17/2003 | US20030134779 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 07/17/2003 | US20030134777 Treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions as antiarrhythmia |
| 07/17/2003 | US20030134775 Therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic |
| 07/17/2003 | US20030134774 Inhibiting the onset of a cardiac disorder in a subject afflicted with cardiac hypertrophy, (2) reducing the activity of PKC- delta or PKC- epsilon present in cardiomyocytes of a subject afflicted with cardiac hypertrophy, and (3) reducing |
| 07/17/2003 | US20030134773 Compositions and methods for treatment of lung transplants |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030134400 Isolation of genes that encode enzymes (Delta 4-desaturase) involved in the conversion of adrenic acid to omega 6-docosapentaenoic acid and omega 3-docosapentaenoic acid to docosahexaenoic acid |
| 07/17/2003 | US20030134350 Zinc finger domain recognition code and uses thereof |
| 07/17/2003 | US20030134344 Her2 gene amplification as detected by fluorescence in situ hybridization |
| 07/17/2003 | US20030134332 Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
| 07/17/2003 | US20030134315 Testing a sample from a cancer patient for the expression of a negative signal transduction factor (NSTF) and for the expression of a positive signal transduction factor (PSTF), selecting chemotherapeutic agent for treatment based on above |
| 07/17/2003 | US20030134314 Assaying the ability of specific polypeptide activity, thereby identifying a compound capable of treating a hematologic disorder |
| 07/17/2003 | US20030134303 Adenine nucleotide-binding protein-directed probes, and methods of their synthesis and use |
| 07/17/2003 | US20030134027 Comprises pectin, alginate, calcium, and fiber; dietetics |